Get a Multi Niche Web™ of Specialized Expertise to Work for Your Oncology Clinical Trial
For the mid-size and smaller biopharma company the stakes are always high for every trial conducted. With limited resources and…
eTMF Best Practice for a Lean Team
The TMF is the official record of the clinical study for Regulatory Authorities, be it the FDA, Health Canada, or…
Canada: For Your Phase 3 Global Trial Expansion
Oncology continues to be the largest and fastest growing therapeutic area in the clinical trials market, and a market dominated…
Doubly Nimble: why you should open global P1 clinical trials in Canada on Day 1
With agility increasingly becoming the most important global driver of success, it’s worth noting that Canadian oncology research center Phase…
Troubleshooting Underperforming Sites – Best Practices
It’s no surprise that an underperforming site can cause significant delays in meeting important accrual targets, data timelines, or study…
Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
The Global Clinical Trials Market was valued at $44.3B USD in 2020, and by 2028 is expected to reach $69.3B…
Lessons Learned Moving Forward – Audit Readiness & Remote Close-Out Visits
The COVID-19 pandemic has required the clinical research industry to find new and innovative ways to monitor investigative sites. Although…
Lessons Learned Moving Forward – Site Support & Remote Close Out
Nearly every aspect of society, including the way scientists conduct the testing of medicines has been affected by the COVID-19…
Why Not Canada for Your Phase 3 Global Trial Expansion?
Pre-pandemic oncology was both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend…
Diversity in Clinical Trial Participants: Canada Holds Promise
Participant diversity in clinical trials can be quite challenging to achieve. With COVID the concern about appropriate demographic representation is…